Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivoximab Combined With Temozolomide in Relapsed/Refractory Glioma
NCT07599371Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in glioma, sponsored by The First Affiliated Hospital of Zhengzhou University. Started Oct 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07599371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599371.